Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.45 |
| ▸ | MMP3 | P08254 | 6/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886812 | 1.00 | MMP2 (0.45) | MMP2MMP3SSTR3ALDH1A1HTT | |
| SCHEMBL3886810 | 1.00 | MMP2 (0.45) | MMP2MMP3SSTR3ALDH1A1HTT | |
| SCHEMBL14314231 | 1.00 | MMP2 (0.45) | MMP2MMP3SSTR3ALDH1A1HTT | |
| SCHEMBL3892600 | 1.00 | MMP2 (0.45) | MMP2MMP3SSTR3ALDH1A1HTT | |
| SCHEMBL3889559 | 0.91 | MMP1 (0.46) | MMP2MMP3 | |
| SCHEMBL3889565 | 0.91 | MMP1 (0.46) | MMP2MMP3 | |
| SCHEMBL3888174 | 0.91 | MMP1 (0.46) | MMP2MMP3 | |
| SCHEMBL3888181 | 0.91 | MMP1 (0.46) | MMP2MMP3 | |
| SCHEMBL3891917 | 0.85 | SSTR3 (0.41) | MMP2MMP3SSTR3ALDH1A1HTT | |
| SCHEMBL3891978 | 0.85 | SSTR3 (0.41) | MMP2MMP3SSTR3ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | claimed |
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | TREH, ADH1A, ADH1C | MMP2 4637/4885MMP3 4820/4885SSTR3 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.